Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Hyperliquid Strategies Inc (PURR)

$5.20 -0.65 (-11.11%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	790.92M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	18,423,000
Avg Vol	4,348,322
Day's Range	N/A - N/A
Shares Out	123.97M
Stochastic %K	5%
Beta	1.58
Analysts	Strong Sell
Price Target	$7.22

Company Profile

Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Address:

477 Madison Avenue, New York, United States

AngeloPerson1993 Mar. 21 at 4:48 PM

$PURR tiny name with under the radar action and that creates decent asymmetry if it starts lifting

0 · Reply

dlkfdk41 Mar. 21 at 7:58 AM

$PURR -11% but nothing happened $HYPE.X

0 · Reply

Dirtdemon75 Mar. 20 at 4:16 PM

$PURR just making regular buys for the ride to 20

1 · Reply

Dirtdemon75 Mar. 19 at 5:20 PM

$PURR

0 · Reply

ReversalTrader7 Mar. 19 at 12:16 AM

$PURR $SPY

0 · Reply

howardlindzon Mar. 18 at 10:10 PM

the hype on hyeprliquid keeps getting more real as people love thew rails this Is bug news from Dow Jones partnership to have perps trading on the $SPY $HYPE.X $PURR ( I have small spec longs In both)

1 · Reply

Was_Up Mar. 18 at 6:30 PM

$PURR

0 · Reply

SJS1983 Mar. 18 at 5:40 PM

$PURR looks like it wants to go.

0 · Reply

shardted Mar. 18 at 5:10 PM

$HYPE.X very $HYPE.X $PURR

0 · Reply

Shopstrat184 Mar. 18 at 3:20 PM

$PURR 24:7:365 SPX perps

0 · Reply

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 6 weeks ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 3 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 3 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 3 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 4 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 5 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 6 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 7 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 8 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 11:30 AM EDT - 8 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 6:00 AM EDT - 8 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 11 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 14, 2024, 4:15 PM EDT - 2 years ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

AngeloPerson1993 Mar. 21 at 4:48 PM

$PURR tiny name with under the radar action and that creates decent asymmetry if it starts lifting

0 · Reply

dlkfdk41 Mar. 21 at 7:58 AM

$PURR -11% but nothing happened $HYPE.X

0 · Reply

Dirtdemon75 Mar. 20 at 4:16 PM

$PURR just making regular buys for the ride to 20

1 · Reply

Dirtdemon75 Mar. 19 at 5:20 PM

$PURR

0 · Reply

ReversalTrader7 Mar. 19 at 12:16 AM

$PURR $SPY

0 · Reply

howardlindzon Mar. 18 at 10:10 PM

1 · Reply

Was_Up Mar. 18 at 6:30 PM

$PURR

0 · Reply

SJS1983 Mar. 18 at 5:40 PM

$PURR looks like it wants to go.

0 · Reply

shardted Mar. 18 at 5:10 PM

$HYPE.X very $HYPE.X $PURR

0 · Reply

Shopstrat184 Mar. 18 at 3:20 PM

$PURR 24:7:365 SPX perps

0 · Reply

ReversalTrader7 Mar. 18 at 2:25 AM

$PURR worth watching 👀

0 · Reply

Doozio Mar. 17 at 8:15 PM

If da $BFLY effect takes hold 🐑 💩 cud get $HYPR $PURR like a 🧠 really $QUIK

0 · Reply

topstockalerts Mar. 17 at 1:43 PM

$PURR Showing strong relative strength versus the market. It’s holding gains while others chop. That’s a bullish sign.

0 · Reply

howardlindzon Mar. 17 at 1:05 PM

this @cheating_stock_investor Is keeping up on $HYPE.X and $PURR for those that want to follow

1 · Reply

cheating_stock_investor Mar. 17 at 12:29 PM

$HYPD $HYPE.X when you have this guy mentioning hype you know it is going mainstream to the non crypto players and you know when he mentions $PURR instead that you're in an undee the radar play with a fast and sudden repricing about to come.

1 · Reply

howardlindzon Mar. 17 at 12:21 AM

$PURR hyperliquid the best looking crypto platform these days $HYPE.X

3 · Reply

MOMOPro Mar. 16 at 10:49 PM

$BMNR $MSTR $BTC $ETH.X $PURR all breaking out of ranges.

0 · Reply

FoxyDreams Mar. 16 at 7:45 PM

/\ @SqueezeSharkie is playing on a completely different level, easily ahead of 90% of traders on this platform. If you’re not following him yet, you’re seriously missing out. Go hit that follow, it’s free and takes two seconds. 💎 $PURR $VANI $FWDI $DTIL >>><<< on watch

0 · Reply

Dirtdemon75 Mar. 16 at 6:13 PM

$PURR

0 · Reply

Dirtdemon75 Mar. 16 at 6:13 PM

$PURR this is like looking into the future.

0 · Reply

spacpack89 Mar. 16 at 4:13 PM

$HYPD which leveraged play is better? $HYPD or $PURR

1 · Reply

spacpack89 Mar. 15 at 3:27 PM

$PURR The popularity of Hyperliquid, whose blockchain technology lets traders buy and sell every day around the clock, reflects how the economic impacts of geopolitical conflicts aren’t limited to the 9:30 a.m.-to-4 p.m. weekday hours of stock exchanges https://fortune.com/2026/03/14/hyperliquid-iran-oil-trade-weekend-markets-24-7/

0 · Reply

1.0.0